Silihan lan utang jangka dawa perusahaan: Biomea (BMEA)

Logo perusahaan publik Biomea (BMEA)

The Biomea Fusion, Inc. (BMEA) price chart on the GURU.Markets platform shows figures at 0.00. The company's business is resilient to economic cycles, as drug development depends on testing phases rather than GDP. Optimized cold chains and reliable carriers ensure seamless supplies. The team consists of top scientists who receive substantial bonuses for developing life-saving therapeutics.

BMEA Utang jangka dawa perusahaan Biomea Fusion, Inc. (04.07.2022 - 29.10.2026)

Ringkesan rincian data analitis Biomea (BMEA)

- rega pasar lan target rega analis:
Rega saham biomeafusion.com|BMEA - Bagan rega target
- indikator kapitalisasi bursa perusahaan:
Nilai pasar Biomea Fusion|BMEA - Nilai Total Perusahaan
- informasi kapitalisasi buku:
Nilai Akuntansi saben Saham Biomea Fusion|BMEA - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku biomeafusion.com|BMEA - Gunggung Aset Perusahaan
- data tingkat utang lan likuiditas finansial:
Rasio Kabeh Utang marang Dana Pribadi Biomea Fusion, Inc.|BMEA - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Biomea Fusion Corp|BMEA - Gunggung utang perusahaan|Utang-utang marang nilai buku Biomea Fusion|BMEA - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Biomea Fusion|Rasio cepet biomeafusion.com
- data bathi lan kelipatan valuasi:
BMEA - Bathi resik
Ringkesan analitik perusahaan:Biomea Fusion, Inc.
Produk merek Biomea Fusion, Inc.

Biomea Fusion, Inc. (BMEA) invests in a highly qualified staff of scientists to develop innovative drugs for cancer and metabolic pathologies. This assessment of the corporation's long-term loans and borrowings on GURU.Markets reflects obligations with maturities exceeding one year. Daily recalculation of the metric eliminates quarterly reporting lags, allowing for precise tracking of debt load dynamics. An optimal leverage balance ensures financial stability and protection against default without suppressing profit growth rates.

Analisis pesaing Biomea Fusion, Inc.

Utang jangka dawa perusahaan ascendispharma.com ASND|MDGL - Utang jangka dawa perusahaan|Silihan lan utang jangka dawa perusahaan CORT (Corcept Therapeutics Inc.)|Rhythm Pharmaceuticals Inc (RYTM) - Utang jangka dawa perusahaan|Kewajiban jangka dawa perusahaan Akero Corp|MTSR (Metsera Inc) - Utang jangka dawa perusahaan|Utang jangka dawa perusahaan moonlaketx.com|Kewajiban jangka dawa perusahaan CRNX (Crinetics)|NAMS (NewAmsterdam Pharma Company) - Silihan lan utang jangka dawa perusahaan|Utang jangka dawa perusahaan Soleno SLNO|FOLD - Kewajiban jangka dawa perusahaan|89bio, Inc. - Utang jangka dawa perusahaan|Utang jangka dawa agios.com|GPCR (Structure Therapeutics Inc.) - Kewajiban jangka dawa perusahaan|MDXG: Gedhene kewajiban jangka dawa|RZLT (Rezolute Corp) - Utang jangka dawa perusahaan|Utang jangka dawa perusahaan Lexicon Corp|Utang jangka dawa perusahaan MBX|Utang jangka dawa perusahaan ALT (altimmune.com)|Utang jangka dawa perusahaan Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Utang jangka dawa|BIOA - Utang jangka dawa perusahaan|QNCX: Utang jangka dawa perusahaan|GUTS: Utang jangka dawa perusahaan|VTVT - Gunggunge utang jangka dawa|Utang jangka dawa perusahaan Agape ATP Corp|Pluri Inc (PLUR) - Gunggunge utang jangka dawa|Utang jangka dawa perusahaan Synlogic, Inc. (SYBX)|Kewajiban jangka dawa perusahaan Lipocine Corporation LPCN|Utang jangka dawa perusahaan MTNB (Matinas BioPharma Holdings)|Spruce Biosciences Inc. - Utang jangka dawa perusahaan|Galecto - Utang jangka dawa perusahaan|Gunggunge utang jangka dawa Carmell Corp. CTCX|Lumos Pharma Corp (LUMO) - Utang jangka dawa perusahaan|Utang jangka dawa Organovo Corp (ONVO)|Utang jangka dawa perusahaan Radius Recycling, Inc.